HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a pilot, open, prospective, non-randomized study to evaluate the safety and efficacy
of switches from etravirine to doravirine, in experienced patients with multiple class
resistance including NNRTI resistance. The other ARV medication (protease inhibitor, entry
inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and
NNRTI, will not be changed.
The study will be performed only on two sites